SUSTAINED-RELEASE METFORMIN (GLUCOPHAGE LONG) IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS


Cite item

Full Text

Abstract

Metformin is first-line drug in the treatment of type 2 diabetes mellitus. Original metformin Glucophage is successfully applied in practice for over 50 years. However, adverse effects on the gastrointestinal tract are common in patients receiving metformin; furthermore, they cause discomfort and in some cases require withdrawal of drug. An innovative form of sustained-release metformin (Glucophage Long®), which is based on a dual polymer matrix (system of diffusion through the gel barrier), allows the effective control of glycemia within 24 hours while taking the drug once a day and provides better tolerability compared with the conventional metformin. This new dosage form can improve patients' adherence to metformin.

References

  1. Старостина Е.Г., Древаль А.В. Бигуаниды в лечении сахарного диабета 2 типа. М., 2000. 104 с.
  2. Lefebvre P. Metformin. The gold standard. A scientific Handbook. Ed. Bailey CJ, Campbell JW, Chan JC. Wiley 2007.
  3. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393-403.
  4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
  5. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "double diabetes" in the Diabetes Control and Complication Trial. Diabetes Care 2007;30(3):707-12.
  6. Hamilton J, Cummings E, Zdravkovic V. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care 2003;26(1):138-43.
  7. Abdelghaffar S, Attia A. Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents. Cochrane Database Syst Rev 2009;21(1):CD006691.
  8. Scarpello JHB. Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes. Br J Vasc Dis 2001;1:28-36.
  9. Paes AHP, Bakker A, Soe-Agnie S-J. Impact of dosage frequency on patient compliance. Diabetes Care 1997;20:1512-17.
  10. Timmins P, Donahue S, Meeker J, Marathe P. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet 2005;44:721-29.
  11. Schwartz S, Fonseca V, Berner B, et al. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care 2006;29(4):759-64.
  12. Fujioka K, Brazg RL, Raz I, et al. Efficacy, dose-response relationship and safety of once-daily extendedrelease metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two doubleblind, placebo-controlled studies. Diabetes Obes Metab 2005;7:28-39.
  13. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997;103:491-97.
  14. Howlett H, Davidson J. New prolonged-release metformin improves gastrointestinal tolerability. Br J Diabetes Vasc Dis 2004;4:273-77.
  15. Fujioka K, Joyal S, Bruce S. Type 2 diabetes patients switched from immediate-release metformin bid to an extended-release qd formulation in a randomized, controlled trial maintain comparable glycemic control. Clin Ther 2003;25:515-29.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies